Recurrent stent thrombosis in a patient with acute coronary syndrome and ischemic colitis: between life-threatening thrombosis and life-threatening bleeding

References

• Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al.; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.
   PubMed Web of Science ®Google Scholar
• Lev EI, Kornowski R, Vaknin-Assa H, Porter A, Teplitsky I, Ben-Dor I, Brosh D, Fuchs S, Battler A, Assali A. Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2008;102:6–11. doi:10.1016/j.amjcard.2008.02.088
   PubMed Web of Science ®Google Scholar
• Turner S, Ketch TR, Gandhi SK, Sane DC. Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J. 2008;155:806–816. doi:10.1016/j.ahj.2007.11.037
   PubMed Web of Science ®Google Scholar
• Feng XQ, Zhu LL, Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res 2017;10:1225–1239. doi:10.2147/JPR.S138698
   PubMed Web of Science ®Google Scholar
• Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016;37:245–252. doi:10.1093/eurheartj/ehv547
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012;5:268–277. doi:10.1016/j.jcin.2012.01.006
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Franchi F, Waksman R, Sweeny JM, Raveendran G, Teng R, Zhao Y, Carlson G, Khan N, Mehran R. Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing Ad Hoc PCI. J Am Coll Cardiol 2016;67:603–613. doi:10.1016/j.jacc.2015.11.044
   PubMed Web of Science ®Google Scholar
• Savonitto S, D’Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M, Klugmann S, De Servi S. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010;104:285–291. doi:10.1093/bja/aep373
   PubMed Web of Science ®Google Scholar
• Nikolic AL, Keck JO. Ischaemic colitis: uncertainty in diagnosis, pathophysiology and management. ANZ J Surg 2018;88:278–283. doi:10.1111/ans.14237
   PubMed Web of Science ®Google Scholar
• Zhang R, Sun JP, Chong J, Liu B, Wang F, Yu CM. Ischemic colitis as a complication of acute myocardial infarction. Int J Cardiol 2015;185:50–51. doi:10.1016/j.ijcard.2015.03.020
   PubMed Web of Science ®Google Scholar
• Rossini R, Tarantini G, Musumeci G, Masiero G, Barbato E, Calabrò P, Capodanno D, Leonardi S, Lettino M, Limbruno U, et al. A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery: surgery after stenting 2. JACC Cardiovasc Interv 2018;11:417–434. doi:10.1016/j.jcin.2017.10.051
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, et al.; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265–274. doi:10.1001/jama.2011.2002
   PubMed Web of Science ®Google Scholar
• Leonardi S, Bhatt DL. Practical considerations for cangrelor use in patients with acute coronary syndromes. Eur Heart J Acute Cardiovasc Care 2017 Jun;1:2048872617707960.
   Google Scholar
• Morici N, Moja L, Rosato V, Sacco A, Mafrici A, Klugmann S, D’Urbano M, La Vecchia C, De Servi S, Savonitto S. Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review. Intern Emerg Med 2014;9:225–235. doi:10.1007/s11739-013-1041-8
   PubMed Web of Science ®Google Scholar
• De Servi S, Morici N, Boschetti E, Rossini R, Martina P, Musumeci G, D’Urbano M, Lazzari L, La Vecchia C, Senni M, et al. Bridge therapy or standard treatment for urgent surgery after coronary stent implantation: analysis of 314 patients. Vascul Pharmacol 2016;80:85–90. doi:10.1016/j.vph.2015.11.085
   PubMed Web of Science ®Google Scholar
• Larsen SB, Grove EL, Würtz M, Neergaard-Petersen S, Hvas AM, Kristensen SD. The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thromb Haemost 2015;114:519–529. doi:10.1160/TH14-12-1007
   PubMed Web of Science ®Google Scholar
• Wessler JD, Giugliano RP. Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials. Eur Heart J Cardiovasc Pharmacother 2015;1:97–106. doi:10.1093/ehjcvp/pvu008
   PubMed Web of Science ®Google Scholar
• Groves EM, Bhatt DL, Steg PG, Deliargyris EN, Stone GW, Gibson CM, Hamm CW, Mahaffey KW, White HD, Angiolillo D, et al. Incidence, predictors, and outcomes of acquired thrombocytopenia after percutaneous coronary intervention: a pooled, patient-level analysis of the CHAMPION Trials (Cangrelor versus standard therapy to achieve optimal management of platelet inhibition). Circ Cardiovasc Interv 2018;11:e005635. doi:10.1161/CIRCINTERVENTIONS.118.006388
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Pollack CV, Weitz JI, Jennings LK, Xu S, Arnold SE, Umstead BR, Mays MC, Lee JS. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med 2019;380:1825–1833. doi:10.1056/NEJMoa1901778
   PubMed Web of Science ®Google Scholar
• Degrauwe S, Roffi M, Lauriers N, Muller O, Masci PG, Valgimigli M, Iglesias JF. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial. Eur Heart J Cardiovasc Pharmacother 2019;5:158–163. doi:10.1093/ehjcvp/pvy031
   PubMed Web of Science ®Google Scholar
• Warlo EMK, Arnesen H, Seljeflot I. A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. Thromb J 2019;17:11. doi:10.1186/s12959-019-0197-5
   PubMed Web of Science ®Google Scholar
• Suleiman A, Khan A, Posimreddy S, Komer C, Shehadeh A. Stent thrombosis secondary to ticagrelor resistance as demonstrated by thromboelastography. J Cardiol Curr Res 2016;6:3.
   Google Scholar
• Angoulvant D, Genet T, Ivanes F. Optimizing DAPT duration in high-risk patients after coronary stent implantation: bleeding risk takes it all. J Am Coll Cardiol 2019;73:755–757. doi:10.1016/j.jacc.2018.11.047
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M, Shaikh Z, Nawaz A, Silva G, Been L, et al. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2019;139:1661–1670. doi:10.1161/CIRCULATIONAHA.118.038317
   PubMed Web of Science ®Google Scholar